Newsletter Subject

Brain Tech: Is It the Future or Just Fiction?

From

primetechstocks.com

Email Address

alerts@awarenessstocks.com

Sent On

Thu, Jul 13, 2023 03:07 PM

Email Preheader Text

Is this run just the beginning or just a well crafted pump... NeuroOne Medical Technologies Corp cla

Is this run just the beginning or just a well crafted pump... [Image] NeuroOne Medical Technologies Corp (NASDAQ: NMTC) claims to be crafting 'highly-sensitive tape recorders' for the brain, and even tools to remove problematic tissue. Sounds fascinating, doesn't it? Or do you think it’s complete BS? One thing that we do know is real is the stock’s recent price action…shares have shot up by 50% over the last two weeks. Is this run just the beginning or just a well crafted pump? NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) 1-month trading range: $1.00- $1.54 Typical average daily volume: 206K Float: ~ 13.5 million NeuroOne Medical Technologies Corp.Business Think of it as a workshop constantly crafting and refining tools for the brain and nervous system. NeuroOne Medical Technologies core specialty lies in thin film electrode technology. This sounds fancy, but essentially, it's like a highly sensitive tape recorder for your brain, continually reading and interpreting electrical signals. The technology is used in two kinds of recording procedures - continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG). These high-tech methods monitor the brain's electrical activity over extended periods, sort of like a surveillance system for your brain. They also work on spinal cord and brain stimulation tools, and devices for a medical procedure called ablation, which is a way of treating diseases by selectively eliminating the problematic tissue. All these developments aim to help patients with neurological disorders such as epilepsy, and Parkinson's disease and even people with chronic pain caused by unsuccessful back surgeries, among other conditions. Teaming up with RBC Medical Innovations, they're trying to develop a radio frequency ablation generator, a device that uses radio waves to heat up and destroy troublesome areas in the body, while leaving the healthy parts intact. [UFqCR14eN6PpkwcryaJcEfqigaT7YbczV6yMgBSsIiGHDPiiLnqSl9alAlEbstM0QNLB4FLUdI_CPbKbMb_mwxOpMAh4ox1up_hlYAJ0XucRjBfOgODv6TvzqmXuefzmwBH12Vq71idiA61lVUJfLzY] Source: [NeuroOne]( While the promises of NeuroOne sound fascinating, as with any medical technology, effectiveness will ultimately be proven through rigorous clinical testing and real-world use. On June 12, the company submitted a 510(k) Application to the FDA for OneRF Ablation System. Essentially, NeuroOne developed a method to use their already installed electrodes (sEEG) to continuously monitor this 'circuit board', and pinpoint any abnormal activity. Once detected, the OneRF™ system can connect these electrodes to a special radio frequency (RF) generator, safely removing the problematic nervous tissue. If the FDA gives the green light, this will be NeuroOne's first step towards introducing this unique RF ablation system in the world of neurology and neurosurgery But remember, this is just a submission and not an approval. There are still several checkpoints to cross before this technology can hit the market. It's a hopeful start, though, and potentially a new avenue to treat neurological disorders. Financials[UmwSv8srI5akdioIuHDTVzAdLbDMQsiPZ8S_e4NOXGGOwZp1BkRYNlU43TcMX0YmQ0IA-T6iFt8KK8B5g0LEnoL40oswSm9Jzc2KP3IPDNUDgs8d6XTgZ-9eYHCYGpGCvQOpUEhuZdy8sEP87KeZXcA] Source: [Stockanalysis.com]( NMTC is experiencing strong revenue growth, going from $2.1 million in 2022 to $4.0 million over the last twelve months. However, substantial operating expenses have led to consistent operating losses. The company is far from being profitable. In addition, cash is a concern. Its negative free cash flow indicates the company spends way more than it’s bringing in. Again, it’s not all negative. The firm’s total assets are growing…but so are its liabilities. But what’s really frustrating for investors is that the company is issuing new shares and diluting current shareholders. Promoter Activity I heard about NMTC via email from one promoter. Here were their main selling points on the stock: - NMTC has a low float of shares, which suggests the potential for high volatility and opportunities for quick gains. - The company has recently submitted a 510(k) application to the FDA for its OneRF™ Ablation System, a transformative medical device. If approved, it could bring significant attention and market buzz to NMTC. - The trend has been bullish lately, as the stock has climbed from $1 to as high as $1.54 in recent trading. - The company's innovative technologies, such as the OneRF™ Ablation System and the Evo® Depth Electrode, are potentially disruptive in the medical field, specifically neurology, indicating future growth potential. - The company's patented technologies have wide-ranging applications in treating various neurological and psychiatric conditions. This versatility adds to its growth potential in the medical device industry. The investor awareness campaign ran from 7/07 to 7/10. They received $8K for their efforts. However, they’ve worked together in the past, and in total, have snagged $465K from NMTC. Straight to the Facts NMTC has been trading well lately. However, it hasn’t seen a lot of volume. Also, given its massive run up…it wouldn’t be surprising if we see an offering soon. Keep it on your watchlist…look for catalysts…and a spike in volume. If you do decide to trade this, it would likely be wise to NOT hold overnight…in case they decide to raise cash and dilute shareholders. Always at your service, Baron Von Stocks Red Oak Media Group, 7940 Ann Arbor St Dexter MI USA 48130 To update contact information or unsubscribe from this list, please [click here](

Marketing emails from primetechstocks.com

View More
Sent On

13/10/2023

Sent On

13/10/2023

Sent On

13/10/2023

Sent On

12/10/2023

Sent On

11/10/2023

Sent On

11/10/2023

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.